Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“BioShield” Law Nears Passage; FDA Proposes “Pre-Pre-IND” Meetings

Executive Summary

FDA counterterrorism regulations will likely face added scrutiny following the expected enactment of Project BioShield, which allows for wider use of investigational products in emergency situations

You may also be interested in...



Ebola Threat Prompts EU To Focus On Adaptive Licensing

The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.

FDA Emergency Use Authorization For Bioterror Drugs Includes HHS Consultation

FDA will consult with an HHS panel when making decisions on which drug candidates could be authorized for emergency use

FDA Emergency Use Authorization For Bioterror Drugs Includes HHS Consultation

FDA will consult with an HHS panel when making decisions on which drug candidates could be authorized for emergency use

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel